3,3'-diindolylmethane · diindolylmethane · I3C metabolite · BioResponse DIM
200 mg · vegan · gluten-free · 90 caps
Affiliate link · we earn from qualifying purchases. No paid placements.
DIM (3,3'-diindolylmethane) is a bioactive compound formed from the digestion of indole-3-carbinol (I3C), found in cruciferous vegetables like broccoli, Brussels sprouts, and cabbage. It influences estrogen metabolism by promoting the conversion of estradiol to 2-hydroxyestrone, a less potent estrogen metabolite.
DIM induces CYP1A1 and CYP1A2 enzymes in the liver, shifting estrogen metabolism toward 2-hydroxylation (beneficial) and away from 16-alpha-hydroxylation (potentially harmful). It also exhibits anti-androgenic, anti-inflammatory, and anti-proliferative effects in hormone-sensitive tissues.
Women with estrogen-dominant conditions, individuals seeking breast health support, those with family history of hormone-related cancers, people interested in cruciferous vegetable supplementation.
Pregnant or breastfeeding women, children, those with hormone-sensitive conditions (unless supervised), individuals taking tamoxifen or other SERMs (potential interaction), people with liver disease.
Pick a depth — minimum to maximal coverage
No full stack configured.
Click individual supplement pills above to buy each on Amazon India.
✓ Morning for consistent estrogen metabolism support
✓ Fat-containing meal improves absorption of this lipophilic compound
DIM induces CYP1A1 and CYP1A2 enzymes in the liver, shifting estrogen metabolism toward 2-hydroxylation (beneficial) and away from 16-alpha-hydroxylation (potentially harmful).
Each bar = one cited trial. Effect varies by methodology, dose, and population.
Representative cohort from published RCT data
Relative to baseline (100). Data from published clinical literature.
see study
→ BioResponse DIM achieved 4–5x higher plasma levels vs standard DIM; well-tolerated (N=11)
see study
→ DIM 150 mg twice daily improved estrogen metabolite ratios in tamoxifen-treated patients (N=130)
see study
→ DIM 300 mg/day for 4–6 weeks modulated estrogen metabolism in BRCA carriers (N=23, pilot)
B · Strong mechanistic rationale; promising biomarker data; no large prevention trials completed; pilot studies small; absorption is limiting factor without enhanced formulation
A plain-English read of the literature behind this supplement. Not a clinical recommendation.
Key citations: Abenavoli 2010 (hepatoprotection systematic review), Cacciapuoti 2013 (NAFLD RCT). richResearch section contains study filters.
How to use DIM specifically for estrogen dominance — the right dose, timing, blood markers to track, and how to know if it is working.
A clinical evidence review of DIM — RCT data, effect sizes, evidence grade, and what the numbers mean for your specific situation.
Everything you need to know about DIM — mechanism, dose, safety, buying guide for India, and what the research actually says.
SacredBod's longer take on DIM — context the structured blocks above don't capture.
DIM is one of the most compelling examples of a food-derived compound with genuine pharmacological activity. Formed when stomach acid condenses indole-3-carbinol (I3C) from cruciferous vegetables, DIM shifts estrogen metabolism toward 2-hydroxylation—a pathway associated with reduced estrogenic potency and potentially lower cancer risk. The mechanistic rationale is robust: DIM induces cytochrome P450 1A1 and 1A2 enzymes in the liver, altering the ratio of 2-hydroxyestrone to 16-alpha-hydroxyestrone in favor of the former.
The absorption challenge is real and has been solved. Reed and colleagues (2008, Cancer Epidemiology, Biomarkers & Prevention, PMID 18843002) demonstrated that standard DIM has poor bioavailability—most of an oral dose passes through the gut unabsorbed. However, a formulation using a proprietary delivery system (BioResponse DIM) achieved 4–5 times higher plasma concentrations. This matters because earlier null results with standard DIM likely reflected insufficient absorption rather than biological inactivity. The absorption-enhanced formulation is now standard in clinical trials.
The clinical evidence is promising but preliminary. Thomson and colleagues (2017, Breast Cancer Research and Treatment, PMID 28391484) conducted a randomized placebo-controlled trial in 130 women taking tamoxifen for breast cancer, testing DIM 150 mg twice daily. The DIM group showed significant improvement in estrogen metabolite ratios, with increased 2-hydroxyestrone and decreased 16-alpha-hydroxyestrone. This is a biomarker study, not an outcome study, but the direction is favorable. Dalessandri and colleagues (2012, Nutrition and Cancer, PMID 22044893) conducted a pilot trial in 23 BRCA mutation carriers—women at extremely high genetic risk for breast cancer—and found that DIM 300 mg daily for 4–6 weeks modulated estrogen metabolism in directions consistent with reduced risk.
The honest framing requires acknowledging the gap between mechanism and proof. DIM has excellent mechanistic rationale, promising biomarker data in high-risk populations, and no serious safety concerns. However, no large-scale prevention trial has demonstrated reduced breast cancer incidence. The compound is appropriate for women with estrogen-dominant symptoms, family history of hormone-related cancers, or those seeking to optimize estrogen metabolism—but it should not be presented as a proven cancer preventive agent. The absorption issue is critical: non-enhanced formulations may be ineffective.
Peptides are physician-only. Tell us a bit and we'll route you to the right specialist.
